All In Biotech

Drug Trial Radar · NCT04486378

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

A Multi-site, Open-label, Phase II, Randomized, Controlled Trial to Compare the Efficacy of RO7198457 Versus Watchful Waiting in Resected, Stage II (High Risk) and Stage III Colorectal Cancer Patients Who Are ctDNA Positive Following Resection

Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 327 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

327

Planned (sponsor's estimate)

Start

Mar 8, 2021

Primary completion

Nov 2026

Study completion Nov 2026

Sponsor

Lead sponsor
BioNTech SEIndustry
Sponsor type
Industry
Collaborators
Genentech, Inc.
First posted
Jul 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-site, open-label, Phase II, randomized, trial to compare the efficacy of RO7198457 versus watchful waiting in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

Conditions

  • Colorectal Cancer Stage II
  • Colorectal Cancer Stage III

Interventions

  • RO7198457 intravenous (IV)Drug

    RO7198457 administered as an IV injection at protocol-specified intervals over 12 months.

  • Observational group (no intervention)Other

    watchful waiting

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival (DFS)Time frame: Through study completion, up to 5 years

Locations

85 sites in 7 countries. Site status is shown where the registry gives one.

  • Marin Cancer Care

    Greenbrae, California

  • Indiana University Melvin and Bren Simon Comprehensive Cancer

    Indianapolis, Indiana

  • Allina Health

    Minneapolis, Minnesota

  • Oncology Hematology Care Clinical Trials

    Cincinnati, Ohio

  • Rhode Island Hospital

    Providence, Rhode Island

  • Sarah Cannon (Tennessee Oncology - Nashville)

    Nashville, Tennessee

  • Texas Oncology, P.A. - Austin

    Austin, Texas

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Texas Oncology-San Antonio Medical Center

    San Antonio, Texas

  • Texas Oncology - Northeast Texas

    Tyler, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • University of Washington

    Seattle, Washington

  • Northwest Cancer Specialists P.C.

    Vancouver, Washington

  • University of Wisconsin Carbone Cancer Center

    Madison, Wisconsin

  • Imeldaziekenhuis General Hospital

    Bonheiden, Belgium

  • VZW Algemeen Ziekenhuis AZ Klina

    Brasschaat, Belgium

  • GHDC (Grand Hopital de Charleroi)

    Charleroi, Belgium

  • AZ Groeninge

    Kortrijk, Belgium

  • Centres Hospitaliers Jolimont

    La Louvière, Belgium

  • Universitaire Ziekenhuizen Leuven

    Leuven, Belgium

  • AZ Delta Roeselare

    Roeselare, Belgium

  • GasthuisZusters Antwerpen - Sint-Augustinus

    Wilrijk, Belgium

  • The Ottawa Hospital Cancer Centre

    Ottawa, Canada

  • Princess Margaret Cancer Centre

    Toronto, Canada

  • Charité - Universitätsmedizin Berlin

    Berlin, Germany

  • Universitaetsklinikum St. Josef-Hospital Bochum

    Bochum, Germany

  • Universitätsklinikum Bonn, Med. Klinik u. Poliklinik I

    Bonn, Germany

  • Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF)

    Frankfurt am Main, Germany

  • Studiengesellschaft BSF

    Halle, Germany

  • Universitätsklinikum Hamburg-Eppendorf

    Hamburg, Germany

  • Hämatologisch-Onkologische Praxis Eppendorf

    Hamburg, Germany

  • Asklepios Klinik Altona

    Hamburg, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • National Center for Tumor Diseases (NCT) Heidelberg

    Heidelberg, Germany

  • SLK-Kliniken Heilbronn GmbH

    Heilbronn, Germany

  • Universitaetsklinikum Leipzig AoeR

    Leipzig, Germany

  • Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR

    Mainz, Germany

  • LMU Klinikum (Campus Großhadern) Medizinische Klinik Universität München

    München, Germany

  • OhO Ostholstein Onkologie

    Oldenburg in Holstein, Germany

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.